Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Amortizatization of Intangibles (2020 - 2025)

Historic Amortizatization of Intangibles for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $2.7 million.

  • Xeris Biopharma Holdings' Amortizatization of Intangibles changed 0.0% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $10.8 million for FY2024, which is 0.0% changed from last year.
  • According to the latest figures from Q3 2025, Xeris Biopharma Holdings' Amortizatization of Intangibles is $2.7 million, which was down 0.0% from $2.7 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Amortizatization of Intangibles high stood at $2.7 million for Q1 2022, and its period low was -$154000.0 during Q1 2021.
  • In the last 5 years, Xeris Biopharma Holdings' Amortizatization of Intangibles had a median value of $2.7 million in 2022 and averaged $2.4 million.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first surged by 186038.96% in 2022, then dropped by 3.69% in 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Amortizatization of Intangibles (Quarter) stood at $903000.0 in 2021, then skyrocketed by 200.22% to $2.7 million in 2022, then changed by 0.0% to $2.7 million in 2023, then changed by 0.0% to $2.7 million in 2024, then changed by 0.0% to $2.7 million in 2025.
  • Its Amortizatization of Intangibles was $2.7 million in Q3 2025, compared to $2.7 million in Q2 2025 and $2.7 million in Q1 2025.